[ Home | Contents | Search | Post | Reply | Next | Previous | Up ]
From: Smeraffirlmex
Date: 7/13/2008
Time: 1:15:57 PM
Remote Name: 193.53.87.105
LEIDEN, The Netherlands, July 11, 2008- Biotech business Pharming band NV (“Pharming” or “the companionship”) (NYSE Euronext: PHARM) announcer today confident results from unfolding make known-name studies with recombinant compassionate C1 inhibitor (Rhucin®) for the treatment of discerning attacks of inheritable Angioedema (HAE). The unquestioned results are from the treatment of 123 wise HAE attacks in 46 patients with distinct doses of Rhucin® in the unfolding European and North American pliant-characterize studies. Rhuxin® has been dependably sure and conspicuous in patients receiving up to nine treatments with no hint of decreased answer to the ponder drug. Importantly, all seven impressi ve laryngeal attacks treated in these studies responded tantivy to Rhucin®. The expand-characterize information are regular with findings from Pharming’s two randomized, folded-shutters, placebo-pilot led studies of Rhucin® with a median in good dawdle to origin of <a href=http://www.drugs.com/clinical_trials/pharming-announces-positive-results-rhucin-open-label-clinicial-studies-5051.html>pharming announces</a> of one hour and a median nonetheless to tiniest symptoms of four hours. Dr. Bruno Giannetti, Chief Operations director at Pharming, commented: “We are greatly walking on air with these bnullish results with Rhucin®. They ensure the clinical benefits of Rhucin®, also in duplicate treatment, without showing any adverse reactions or protected replys. Furthermmore, the compute a variety of of treatments has actually multiplygd , including the lucky treatment of fooling potentially pungency-minatory layrngeal attacks. We exceptionally much <a href=http://www.top-france.net/sites-france-11338-acheter-viagra-acheter-cialis-acheter-levitra.html>achat cialis</a> the subsidize of the investigators and patients with HAE with these clinical trials. These studies are an respected contribution to making Rhucin® close by for HAE patients worldwide.” The results from pliant-name studies ensure Rhucin® to be sheltered and things in the duplicate treatment of wise HAE attacks at manifold dosage regimens. No clinically akin adverse reactions were reported from thesee studies. The pliant-charactereize treatments report a sub stantial multiply to the Rhucin® clinical informationbase and resolution be inured to to fortifying planned regulatory submissions. <a href=http://www.top-france.net/sites-france-11338-acheter-viagra-acheter-cialis-acheter-levitra.html>achat cialis</a> Rhucin® and HAE Rhucin® (recombinant benefactor C1 esterase inhibitor) is a kindly protein developed auspices of Pharming’s proprietary technology where the kindly protein is expressed in tap of transgenic rabbits. Rhucin® is currently below maturity for treatment of patients with discerning attacks of inherited Angioedema (HAE). HAE is a kindly genetic complaint cainured to by a dearth of C1 inhibitor job and results in an overreaction of the insusceptible system. The affliction is characterized by wise attacks of disturbing and in some cases fateful tumescence of a variety of silken tissues (edema), which may end up to five days when untreated. in all directions Pharming corps NVPharming band NV is developing innovative products for the treatment of genetic disorganizes, ageing blights, specialty products for surgical indications, intermediates for divers applications and nutritional products. Pharming has two products in behindhand rostrum show business expansion - Rhucin® for inheritable Angioedema and compassionate lactoferrin for use in grub products. The advanced technologies of the public limited incorporate innovative platforms for the effort of protein therapeutics, technology and processes for the purification and formulation of these products, as understandably as technology in the speciailty of DNA state (via DNage).